Browsing Clinical Studies by author "Gurel, Bora"
Now showing items 1-20 of 21
-
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.
Fletcher, CE; Deng, L; Orafidiya, F; Yuan, W; Lorentzen, MPGS; et al. (BMC, 2022-03-22)BACKGROUND: miR-346 was identified as an activator of Androgen Receptor (AR) signalling that associates with DNA damage response (DDR)-linked transcripts in prostate cancer (PC). We sought to delineate the impact of miR-346 ... -
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb, A; Herranz, N; Arce-Gallego, S; Miranda, S; Buroni, L; et al. (ELSEVIER, 2020-11-08)BACKGROUND: Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. OBJECTIVE: To characterise ATM-deficient ... -
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Carreira, S; Porta, N; Arce-Gallego, S; Seed, G; Llop-Guevara, A; et al. (AMER ASSOC CANCER RESEARCH, 2021-11-01)PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed ... -
CD38 in Advanced Prostate Cancers.
Guo, C; Crespo, M; Gurel, B; Dolling, D; Rekowski, J; et al. (ELSEVIER, 2021-02-01)BACKGROUND: CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have not been ... -
Characterizing CDK12-Mutated Prostate Cancers.
Rescigno, P; Gurel, B; Pereira, R; Crespo, M; Rekowski, J; et al. (AMER ASSOC CANCER RESEARCH, 2020-09-28)PURPOSE: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated ... -
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies.
Liang, Y; Jeganathan, S; Marastoni, S; Sharp, A; Figueiredo, I; et al. (AMER ASSOC CANCER RESEARCH, 2021-04-15)PURPOSE: Although enzalutamide (ENZ) has been widely used to treat de novo or castration-resistant metastatic prostate cancer, resistance develops and disease progression is ultimately inevitable. There are currently no ... -
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer.
Hermanova, I; Zúñiga-García, P; Caro-Maldonado, A; Fernandez-Ruiz, S; Salvador, F; et al. (ROCKEFELLER UNIV PRESS, 2020-06-01)Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form ... -
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
Zafeiriou, Z; Bianchini, D; Chandler, R; Rescigno, P; Yuan, W; et al. (ELSEVIER SCIENCE BV, 2019-01-01)Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, ... -
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2020-04-01)The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, ... -
Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer.
Grochot, R; Carreira, S; Miranda, S; Figueiredo, I; Bertan, C; et al. (ELSEVIER, 2023-06-01)BACKGROUND: Germline mutations in the ataxia telangiectasia mutated (ATM) gene occur in 0.5-1% of the overall population and are associated with tumour predisposition. The clinical and pathological features of ATM-mutated ... -
HER-3 Expression and MEK Activation in Non-small Cell Lung Cancer
Manickavasagar, T; Yuan, W; Carreira, S; Gurel, B; Miranda, S; et al. (Research Square, 2020-08-26)<h4>Background: </h4> HER-3 has a role in pathogenesis and development of resistance to targeted therapies in non-small cell lung cancer (NSCLC). MethodsWe analysed tumour samples from 45 patients with adenocarcinoma of ... -
HER3 expression and MEK activation in non-small-cell lung carcinoma.
Manickavasagar, T; Yuan, W; Carreira, S; Gurel, B; Miranda, S; et al. (FUTURE MEDICINE LTD, 2021-04-09)AIM: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression. MATERIALS & METHODS: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 ... -
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil, V; Miranda, S; Riisnaes, R; Gurel, B; D'Ambrosio, M; et al. (AMER ASSOC CANCER RESEARCH, 2021-12-15)It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that ... -
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
Paschalis, A; Welti, J; Neeb, AJ; Yuan, W; Figueiredo, I; et al. (AMER ASSOC CANCER RESEARCH, 2021-02-15)Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically important variant. In this study, ... -
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Minchom, A; Yuan, W; Crespo, M; Gurel, B; Figueiredo, I; et al. (BMJ PUBLISHING GROUP, 2020-03-01)BACKGROUND: This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge. CASE PRESENTATION: A 77-year-old woman with advanced epithelioid ... -
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Mateo, J; Porta, N; Bianchini, D; McGovern, U; Elliott, T; et al. (ELSEVIER SCIENCE INC, 2020-01-01)BACKGROUND: Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and ... -
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
Papadatos-Pastos, D; Yuan, W; Pal, A; Crespo, M; Ferreira, A; et al. (BMJ PUBLISHING GROUP, 2022-06-01)BACKGROUND: Data suggest that immunomodulation induced by DNA hypomethylating agents can sensitize tumors to immune checkpoint inhibitors. We conducted a phase 1 dose-escalation trial (NCT02998567) of guadecitabine and ... -
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Paschalis, A; Sheehan, B; Riisnaes, R; Rodrigues, DN; Gurel, B; et al. (ELSEVIER, 2019-10-01)BACKGROUND: Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility. OBJECTIVE: To elucidate PC PSMA expression and associate this with defective DNA damage repair ... -
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.
Biondo, A; Pal, A; Riisnaes, R; Shinde, R; Tiu, C; et al. (Elsevier BV, 2021-01-11)Early-phase cancer clinical trials are becoming increasingly accessible for patients with advanced cancer who have exhausted standard treatment options and later phase trial options. Many of these trials mandate research ... -
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti, J; Sharp, A; Brooks, N; Yuan, W; McNair, C; et al. (AMER ASSOC CANCER RESEARCH, 2021-05-01)Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional ...